Surface Modification of Bi2O3 Nanoparticles with Biotinylated β-Cyclodextrin as a Biocompatible Therapeutic Agent for Anticancer and Antimicrobial Applications

Bismuth oxide nanoparticles with appropriate surface chemistry exhibit many interesting properties that can be utilized in a variety of applications. This paper describes a new route to the surface modification of bismuth oxide nanoparticles (Bi2O3 NPs) using functionalized beta-Cyclodextrin (beta-CD) as a biocompatible system. The synthesis of Bi2O3 NP was done using PVA (poly vinyl alcohol) as the reductant and the Steglich esterification procedure for the functionalization of beta-CD with biotin. Ultimately, the Bi2O3 NPs are modified using this functionalized beta-CD system. The particle size of the synthesized Bi2O3 NPs is found to be in the range of 12-16 nm. The modified biocompatible systems were characterized using different characterization techniques such as Fourier transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM), scanning electron microscopy (SEM), X-ray powder diffraction (XRD) and Differential Scanning Calorimetric analysis (DSC). Additionally, the antibacterial and anticancerous effects of the surface-modified Bi2O3 NP system were also investigated.

Automated summary

Bismuth oxide nanoparticles (Bi2O3 NPs), modified using functionalized beta-Cyclodextrin (beta-CD) as a biocompatible system, have interesting properties that can be applied in various applications. The synthesis of Bi2O3 NPs was achieved using poly vinyl alcohol (PVA) as a reductant, and the beta-CD was functionalized with biotin through the Steglich esterification procedure. The modified Bi2O3 NP system was characterized using various techniques, and its antibacterial and anticancer effects were also investigated.